QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-downgrades-fulcrum-therapeutics-to-sector-perform-lowers-price-target-to-4

RBC Capital analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Sector Perform and lowers...

 hc-wainwright--co-downgrades-fulcrum-therapeutics-to-neutral-lowers-price-target-to-4

HC Wainwright & Co. analyst Andrew Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the...

 leerink-partners-downgrades-fulcrum-therapeutics-to-market-perform-announces-4-price-target

Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and...

 b-of-a-securities-downgrades-fulcrum-therapeutics-to-underperform-lowers-price-target-to-2

B of A Securities analyst Tazeen Ahmad downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Underperform and lowers...

 stifel-downgrades-fulcrum-therapeutics-to-hold-lowers-price-target-to-3

Stifel analyst Dae Gon Ha downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $2...

 fulcrum-therapeutics-suspends-rare-muscular-disease-candidate-after-disappointing-data-from-pivotal-trial

Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The c...

 cantor-fitzgerald-downgrades-fulcrum-therapeutics-to-neutral

Cantor Fitzgerald analyst Kristen Kluska downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Neutral.

Core News & Articles

CSBR: 59% | Champions Oncology shares are trading higher after the company reported better-than-expected Q1 financial results. ...

 fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-rare-genetic-muscle-disease

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...

 b-of-a-securities-upgrades-fulcrum-therapeutics-to-neutral-raises-price-target-to-10

B of A Securities analyst Tazeen Ahmad upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Underperform to Neutral and raises t...

 hc-wainwright--co-reiterates-buy-on-fulcrum-therapeutics-maintains-17-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...

 fulcrum-therapeutics-q2-eps-totals-087-compared-with-038-loss-yoy-company-exits-quarter-with-cash-and-equivalents-worth-2738m

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly earnings of $0.87 per share his is a 328.95 percent increase over losses ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION